Kodiak Sciences Q1 EPS Estimate Lowered by HC Wainwright

Kodiak Sciences Inc. (NASDAQ:KOD) – HC Wainwright decreased their Q1 2026 EPS estimates for shares of Kodiak Sciences in a report issued on Wednesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.94) per share for the quarter, down from their previous forecast of ($0.75). HC Wainwright currently has a “Buy” rating and a $58.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($1.94) EPS, FY2029 earnings at $0.19 EPS and FY2030 earnings at $3.05 EPS.

Several other equities analysts have also recently issued reports on KOD. Weiss Ratings reissued a “sell (e+)” rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. UBS Group raised their target price on Kodiak Sciences from $50.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Kodiak Sciences currently has an average rating of “Moderate Buy” and an average price target of $35.43.

Kodiak Sciences Stock Performance

Shares of KOD opened at $40.63 on Friday. The business’s 50-day moving average is $26.37 and its two-hundred day moving average is $22.83. The company has a market capitalization of $2.51 billion, a P/E ratio of -9.41 and a beta of 2.39. Kodiak Sciences has a fifty-two week low of $1.92 and a fifty-two week high of $45.60.

Kodiak Sciences (NASDAQ:KOD) last issued its earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KOD. EverSource Wealth Advisors LLC raised its position in shares of Kodiak Sciences by 1,221.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock worth $28,000 after acquiring an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Kodiak Sciences during the 4th quarter valued at about $29,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Kodiak Sciences in the 4th quarter valued at about $72,000. Strs Ohio acquired a new position in Kodiak Sciences in the 4th quarter worth about $87,000. Finally, Aster Capital Management DIFC Ltd acquired a new position in Kodiak Sciences in the 4th quarter worth about $119,000. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Trending Headlines about Kodiak Sciences

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: HC Wainwright keeps a “Buy” rating and a $58 price target on KOD despite trimming earnings forecasts — a sign that at least one major broker still sees meaningful upside beyond near‑term losses. MarketBeat Kodiak page
• Neutral Sentiment: Healio reports that “Zenkuda” showed superiority to sham in a Phase 3 diabetic retinopathy study. Investors will evaluate whether this readout affects Kodiak directly (if Zenkuda is related to Kodiak’s pipeline) or if it changes the competitive landscape in retinal therapeutics. Zenkuda Phase 3 readout
• Neutral Sentiment: Kodiak issued a corporate release summarizing recent business highlights and its fourth‑quarter and full‑year 2025 financial results; investors should read the filing for cash runway, revenue/expense items and any pipeline milestone updates that could materially affect valuation. Kodiak Q4/FY2025 results
• Negative Sentiment: Multiple analyst teams (HC Wainwright and Lifesci Capital) cut near‑term and multi‑year EPS estimates in reports issued April 1 — revisions include larger expected losses for Q1–Q4 2026 and downgraded FY2026 and out‑year forecasts (examples: HC Wainwright moved FY2026 to about ($3.56) EPS; Lifesci trimmed FY2026 toward ($2.52) EPS). Those downgrades increase short‑term downside risk as they raise expectations for continued operating losses and may push markets to reprice growth/timing assumptions. Analyst revision summaries

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.